Previously submitted to: JMIR Cancer (no longer under consideration since Jan 24, 2023)
Date Submitted: Jun 16, 2022
Open Peer Review Period: Apr 25, 2022 - Jun 20, 2022
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
mHealth Technology as a Help Tool during Breast Cancer Treatment: A Content Focus Group
ABSTRACT
Purpose: To assess usability, feasibility, and acceptability of patients with breast cancer of a mobile health technology as a tool to help obtain patient-reported results (PROM), follow-up of side effects and results in the quality of life, reinforcing adherence to treatment and communication with the doctor. Approach: Focus groups. Setting: Hospital Clinic from Barcelona. Participants: Survivors n=5 (M ¼ 63.2 years; 100% female; 100% European Spanish) of breast cancer. Intervention: A fully functional mHealth app prototype. Xemio App provides side effect tracking, social agendas, and personalized disease information for breast cancer patients. Method: Semi-structured focus groups were conducted and assessed using thematic data analysis to identify the benefits, concerns, needs, and expectations of the Xemio App.
Results:
convenience and reliable content were the main benefits of using the application, while the difficulty of use and the means of interaction were the main concern. Participants felt positive adding a calendar network to the app and downloading the recorded symptoms. Finally, participants were waiting to hear release news about Xemio App from their healthcare provider. Conclusion: Guidance and credible health information on breast cancer survivors should be accessible and convenient for all people affected by the disease. The next step is to investigate how the use of the Xemio App affects the quality of life of breast cancer survivors, involving the continuous evolution of the app to provide better and adapted content.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.